Senior Vice President and Head of US Business Development for, Otsuka America Pharmaceuticals
Ron Newbold is Senior Vice President and Head of US Business Development for Otsuka America Pharmaceuticals, where his responsibilities are to identify novel new therapeutic programs in Otsuka’s core areas of Neuroscience, Oncology and Renal diseases that will benefit patients globally. Ron joined Otsuka in November 2017 with 24 years of Business Development and Alliance Management experience leading business teams in negotiating over $1.5 billion in announced pharma / biotech deals. He is experienced leading search & evaluation and due diligence both in big pharma and in smaller biotechnology companies to effect corporate M&A transactions, collaborative academic partnerships and start-up company investments.
After receiving his PhD from the University of Rochester and a postdoctoral fellowship at Harvard University, he joined Merck where he was ultimately responsible for Strategic Research Initiatives within External Scientific Affairs. Following 14 years with Merck, Ron led BD for three US-based biotech companies (Sentigen Biosciences, Celldex Therapeutics, and Auspex Pharmaceuticals) prior to joining Pfizer as Vice President of their Global Scouting Group. While at Pfizer, Ron managed a team of scientists in over 10 countries who evaluated and proposed partnerships of scientific value that broadened Pfizer’s early-stage pipelline. He started and led the Pfizer Seed Fund (created through an evolution of the Pfizer Incubator) and over the past 4 years was Board Observer to Ab Initio, Aquinnah, Circle Pharmaceuticals, Lumena (acquired by Shire), Molecular Stethoscopes, Neoantigenics, Storm Therapeutics, and a Scientific Advisory Board member to NeoMED. He remains on the Board of the Licensing and Venture Group at the University of Virginia, where he is Vice Chairman.